Yale’s Department of Psychiatry Chair to Join Clearmind Medicine

Post published:June 21, 2022
Post category:Press Release

Dr. John H. Krystal, world-leading expert in alcoholism and depression, will serve on scientific advisory board

Source link

Tags: Clearmind Medicine

Leave a Reply Cancel reply

Pα+ Psychedelic Bulletin #199: Lykos Takeover Nears Completion; Fewer than 100 Patients Received Psychedelics in Australia During First 18 Months of Access; Ibogaine Bill Clears Texas Legislature Amid THC CrackdownMay 30, 2025
New CEO Tapped as Gracias and Hohn Close In on Lykos Takeover • Data Reveals Fewer than 100 Patients Received Psychedelics in Australia During First 18 Months of Access • Ibogaine Bill Clears Texas Legislature Amid THC Crackdown • and more…
Can a State Fast-Track a Psychedelic Breakthrough? Inside Texas’ Plan to Fund Ibogaine TrialsMay 28, 2025
Texas is on the verge of launching the largest publicly funded psychedelic research initiative in U.S. history: a $50 million public-private partnership to support FDA-approvable ibogaine trials. The initiative has drawn support from high-profile figures like Rick Perry, but also concerns over safety, cost, access, and the lack of recognition for Indigenous knowledge. We take a look at the bold plan, the political manoeuvring that made it possible, and the questions that still remain.
Gilgamesh’s Next-Gen Psychedelic GM-2505 Prints Impressive Results in Phase 2a Major Depressive Disorder StudyMay 27, 2025
As Gilgamesh Pharmaceuticals is set to share positive results from its Phase 2a study of GM-2505 (aka bretisilocin, a serotonergic psychedelic) in major depressive disorder later today at ASCP, we speak with the company’s Chief Strategy and Development Officer Jorge Quiroz and Chief Operating Officer Yoni Falkson to dig a little deeper into the study, its results, and the company’s plans for the candidate.
Matt Zorn, the Government’s Former Adversary, Is Now Its Psychedelics CzarMay 24, 2025
Matt Zorn made his name suing federal agencies over cannabis and psychedelics policy. Now, he’s inside the system as Deputy General Counsel at HHS, with what appears to be a mandate over psychedelics reform. Here, we recount Zorn's path from 'thorn in the side' of the federal government to insider, what we might expect from him in his new role, and how insiders are reacting to the news.
Pα+ Psychedelic Bulletin #198: New Data Offers Look at Spravato’s Long-Term Use, Highlights Psychedelic Opportunity; MAHA Report Slams Psychiatric Meds; Momentum Builds for BeckleyMay 23, 2025
New Data Offers Look at Spravato’s Long-Term Use, Highlights Opportunity for Psychedelics • MAHA Report Slams Psychiatric Drug Use Among America’s Youth, Trump Era Drug Policy Priorities Raise Questions for Psychedelics • Beckley Psytech’s Small Study Supports Adjunctive Use of 5-MeO-DMT with SSRIs in TRD • and more...

Yale’s Department of Psychiatry Chair to Join Clearmind Medicine

Leave a Reply Cancel reply

Psychedelic Alpha

Quick Links

Newsletter

Subscribe to Our Free Newsletter

Join Pα+ for Premium Insights